Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02161510 | Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002) | PHASE1 | COMPLETED | 13 | — | — | Jul 1, 2014 | Apr 1, 2015 | Jun 8, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| Part I: MK-2248 200 mg (Panel A) | EXPERIMENTAL | HCV participants will take MK-2248 200 mg by mouth once daily for 7 days. |
| Part I: MK-2248 ≤800 mg (Panel B) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part I: MK-2248 ≤800 mg (Panel C) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth for 7 days. |
| Part I: MK-2248 ≤800 mg (Panel D) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part II: MK-2248 200 mg (Panel E) | EXPERIMENTAL | HCV participants will take MK-2248 200 mg by mouth once daily for 7 days. |
| Part II: MK-2248 ≤800 mg (Panel F) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part II: MK-2248 ≤800 mg (Panel G) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part II: MK-2248 ≤800 mg (Panel H) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part III: MK-2248 ≤800 mg (Panel I) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part III: MK-2248 ≤800 mg (Panel J) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Name | Type | Description |
|---|---|---|
| MK-2248 | DRUG | MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days |
Inclusion Criteria: * clinical diagnosis of chronic HCV defined by positive serology for HCV or positive HCV RNA for at least 6 months and detectable HCV RNA in peripheral blood ≥10\^5 IU/mL at screening * Body Mass Index (BMI) ≥18 to \<37 kg/m\^2 * in good health other than HCV infection with norm...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |